Compare Anheuser-Busch Inbev SA (BUD) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Novavax Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.64 (market cap $159.01B), while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: Anheuser-Busch Inbev SA is far larger — about 121.4× Novavax Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| BUD | NVAX | |
|---|---|---|
Market Cap | $159.01B | $1.31B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $11.19 |
52-Week Low | $57.93 | $6.22 |
Enterprise Value | $223.42B | $889.30M |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $83.09, down 0.8% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q1 and Q2 2026 but missing in Q4 2025. The company maintains solid profitability with a 14.9% net income margin and positive cash flow trends. News highlights institutional activity and earnings discussions, with a consensus price target of $90.17 suggesting upside potential.
The outlook for BUD is positive, driven by earnings growth projections and a favorable valuation with a P/E of 17.37. Risks include competitive pressures and macroeconomic volatility, but institutional support and bullish analyst ratings indicate confidence in continued performance. The stock presents a growth opportunity with manageable risks for investors seeking exposure to the consumer staples sector.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
